UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000042940 |
|---|---|
| Receipt number | R000049004 |
| Scientific Title | A Study on the Effect of Food Containing Plant Extract on Platelet Aggregation -A Randomized, Double-blind, Placebo-controlled, Parallel-group Study- |
| Date of disclosure of the study information | 2021/01/08 |
| Last modified on | 2021/12/24 15:22:44 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A Study on the Effect of Food Containing Plant Extract on Platelet Aggregation
-A Randomized, Double-blind, Placebo-controlled, Parallel-group Study-
Acronym
A Study on the Effect of Food Containing Plant Extract on Platelet Aggregation
Scientific Title
A Study on the Effect of Food Containing Plant Extract on Platelet Aggregation
-A Randomized, Double-blind, Placebo-controlled, Parallel-group Study-
Scientific Title:Acronym
A Study on the Effect of Food Containing Plant Extract on Platelet Aggregation
Region
| Japan |
Condition
Condition
No
Classification by specialty
| Adult |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To confirm the effect of food containing plant extract on platelet aggregation
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
platelet aggregation
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Double blind -all involved are blinded
Control
Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Food |
Interventions/Control_1
Foods containing plant extract, 12 weeks consumption
Interventions/Control_2
Foods not containing plant extract, 12 weeks consumption
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 40 | years-old | <= |
Age-upper limit
| 65 | years-old | > |
Gender
Male and Female
Key inclusion criteria
(1) Healthy men and women aged 40 to 64 years old.
(2) Subjects with a BMI < 30.
(3) Subjects who can make self-judgment and voluntarily give written informed consent.
Key exclusion criteria
(1)Subjects who have a chronic disease and regularly use medications.
(2) Subjects who cannot stop using supplements, and/or functional foods (including Food for Specified Health Uses or Foods with Function Claims) during the test periods.
(3) Subjects with a history and/or presence of serious diseases (e. g., liver disease, kidney disease, heart disease, respiratory disease, endocrine disease, and/or metabolic disease).
(4) Subjects who had a history of digestive diseases and/or underwent a surgical procedure for digestive disease.
(5) Subjects who declared allergic reactions to foods.
(6) Subjects who had excessive alcohol intake of > 60 g/day of pure alcohol equivalent or habit of drinking not less than five days a week.
(7)Subjects with a history of and/or current drug addiction and/or alcoholism.
(8) Subjects unable to cease drinking for two days before each measurement.
(9) Subjects who are shift workers and/or night-shift workers.
(10) Subjects who were pregnant or planned to become pregnant or breastfeed during the study period.
(11) Subjects who had donated over 200 mL of blood and/or blood components within the last one month prior to the current study or over 400 mL of blood and/or blood components within the three months prior to the current study.
(12) Subjects who were planning to participate and/or had participated in other clinical studies within the month prior to the commencement of the current study.
(13) Subjects who were judged as unsuitable for the current study by screening tests.
(14) Subjects who were judged as unsuitable for the current study by the investigator for other reasons.
Target sample size
60
Research contact person
Name of lead principal investigator
| 1st name | Toru |
| Middle name | |
| Last name | Sagami |
Organization
Shinagawa Season Terrace Health Care Clinic
Division name
Doctor
Zip code
108-0075
Address
The 5th floor of Shinagawa season terrace, 1-2-70, Konan, Minato-ku, Tokyo
TEL
03-3452-3382
shibaura@sempos.or.jp
Public contact
Name of contact person
| 1st name | Yoshika |
| Middle name | |
| Last name | Komori |
Organization
KSO Corporation
Division name
Sales department
Zip code
105-0023
Address
1-9-7 Shibaura, Minato-ku, Tokyo
TEL
03-3452-7733
Homepage URL
yoshi@kso.co.jp
Sponsor or person
Institute
KSO Corporation
Institute
Department
Personal name
Funding Source
Organization
TOYO SHINYAKU Co., Ltd.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Ethical Committee of Nihonbashi Cardiology Clinic
Address
Kyodo Bldg. #201, 13 - 4 Nihonbashi Kodenmacho, Chuo-ku, Tokyo
Tel
03-5641-4133
niho-jimucho@well-sleep.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2021 | Year | 01 | Month | 08 | Day |
Related information
URL releasing protocol
https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000049004
Publication of results
Published
Result
URL related to results and publications
http://www.pieronline.jp/content/article/0386-3603/49100/1749
Number of participants that the trial has enrolled
60
Results
Statistically significant difference was confirmed in the primary outcome.
Results date posted
| 2021 | Year | 12 | Month | 24 | Day |
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Males and females aged 40 to 64 years old.
Participant flow
Enrolled(n=60)
Completed(n=60)
Analysed(n=50)
Adverse events
No adverse events were observed that be related to test food.
Outcome measures
platelet aggregation
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Main results already published
Date of protocol fixation
| 2020 | Year | 12 | Month | 10 | Day |
Date of IRB
| 2020 | Year | 12 | Month | 14 | Day |
Anticipated trial start date
| 2021 | Year | 01 | Month | 09 | Day |
Last follow-up date
| 2021 | Year | 08 | Month | 02 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2021 | Year | 01 | Month | 07 | Day |
Last modified on
| 2021 | Year | 12 | Month | 24 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049004
